| Literature DB >> 24736685 |
Jaithri Ananthapavan1, Gary Sacks2, Marj Moodie3, Rob Carter4.
Abstract
The discipline of economics plays a varied role in informing the understanding of the problem of obesity and the impact of different interventions aimed at addressing it. This paper discusses the causes of the obesity epidemic from an economics perspective, and outlines various justifications for government intervention in this area. The paper then focuses on the potential contribution of health economics in supporting resource allocation decision making for obesity prevention/treatment. Although economic evaluations of single interventions provide useful information, evaluations undertaken as part of a priority setting exercise provide the greatest scope for influencing decision making. A review of several priority setting examples in obesity prevention/treatment indicates that policy (as compared with program-based) interventions, targeted at prevention (as compared with treatment) and focused "upstream" on the food environment, are likely to be the most cost-effective options for change. However, in order to further support decision makers, several methodological advances are required. These include the incorporation of intervention costs/benefits outside the health sector, the addressing of equity impacts, and the increased engagement of decision makers in the priority setting process.Entities:
Mesh:
Year: 2014 PMID: 24736685 PMCID: PMC4025046 DOI: 10.3390/ijerph110404007
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Cost-effectiveness of primary prevention versus treatment (and secondary prevention) interventions from the Assessing Cost-Effectiveness (ACE)-Obesity and ACE-Prevention studies.
| Cost-effectiveness | Intervention Classification ≠ | |
|---|---|---|
| Cost-saving |
|
|
| Family-based General Practitioner (GP) programme targeted at obese children [ | School (curriculum)-based education programme to reduce television viewing [ | |
| Cost-effective | Orlistat (obese adolescents | Multi-faceted school (curriculum)-based programme without an active physical activity component [ |
| Not cost-effective | Sibutramine (obese adults) | Walking school bus [ |
Notes: The costs included in the economic analyses are the costs of intervention implementation, delivery and the healthcare ramification costs or cost offsets. Productivity costs have not been included. Interventions with net cost-effectiveness results (includes cost offsets) which are cost-saving. Interventions with incremental cost-effectiveness ratios (ICER) below the threshold value of AUD 50,000 per DALY averted. Interventions with ICER above the threshold value of AUD 50,000 per DALY averted. Orlistat is restricted for use in adults only in Australia. Results were cost-saving when the intervention was targeted at obese adults with BMI > 40. * Withdrawn from Australian in 2010. School and community based intervention aimed to increase active transport. Although not restricted/targeted, the majority of participants were overweight or obese.
Cost-effectiveness of program versus policy interventions from the Assessing Cost-Effectiveness (ACE)-Obesity and ACE-Prevention studies.
| Cost-effectiveness | Intervention Classification ≠ | |
|---|---|---|
| Cost-saving |
|
|
| Family-based GP programme targeted at obese children [ | School (curriculum)-based education programme to reduce television viewing [ | |
| Cost-effective | Family-based GP programme targeted at overweight and moderately obese children [ | Multi-faceted school (curriculum)-based programme without an active physical activity component [ |
| Not cost-effective ∫ | Walking school bus [ | |
Notes: The costs included in the economic analyses are the costs of intervention implementation, delivery and the healthcare ramification costs or cost offsets. Productivity costs have not been included. Individualised treatment interventions (e.g., Laparoscopic adjustable gastric banding and pharmacotherapy) have not been included in this table. Interventions with net cost-effectiveness results (includes cost offsets) which are cost-saving. Interventions with incremental cost-effectiveness ratios (ICER) below the threshold value of AUD 50,000 per DALY averted. Interventions with ICER above the threshold value of AUD 50,000 per DALY averted. α School and community based intervention aimed to increase active transport. Although not restricted/targeted, the majority of participants were overweight or obese.
Cost-effectiveness of interventions aimed at food intake and physical activity from the Assessing Cost-Effectiveness (ACE)-Obesity and ACE-Prevention studies.
| Cost-effectiveness | Intervention Classification ≠ | |||
|---|---|---|---|---|
| Cost-saving |
|
|
| |
| School-based education programme to reduce sugar-sweetened drink consumption [ | School (curriculum)-based education programme to reduce television viewing [ | |||
| Cost-effective | Orlistat (obese adolescents | Family-based GP programme targeted at overweight and moderately obese children [ | ||
| Not cost-effective | Sibutramine (obese adults) | Walking school bus [ | Lighten up to a healthy lifestyle weight-loss programme for adults | |
Notes: The costs included in the economic analyses are the costs of intervention implementation, delivery and the healthcare ramification costs or cost offsets. Productivity costs have not been included. Interventions with net cost-effectiveness results (includes cost offsets) which are cost-saving. Interventions with incremental cost-effectiveness ratios (ICER) below the threshold value of AUD 50,000 per DALY averted. Interventions with ICER above the threshold value of AUD 50,000 per DALY averted. Orlistat is restricted for use in adults only in Australia. Results were cost-saving when the intervention was targeted at obese adults with BMI > 40. * Withdrawn from Australian in 2010. School and community based intervention aimed to increase active transport. Although not restricted/targeted, the majority of participants were overweight or obese.
Figure 1Interventions from the Assessing Cost Effectiveness (ACE) Obesity and ACE-Prevention studies, mapped to the continuum of obesity determinants and solutions.